TARSILA 실제 세계 증거 연구 (TARSILA)
브라질 영아에서 RSV 관련 급성 호흡기 질환에 대한 모체 RSVpreF 백신 접종의 실제 효과 (TARSILA 연구): 다기관, 전향적, 검사 음성, 환자-대조군 연구
The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Tarsila comprises two multicenter, prospective, case-control studies using a test-negative design in Southern Brazil (states of Rio Grande do Sul, Santa Catarina, and Paraná). The Tarsila Inpatient study will enroll infants hospitalized due to acute respiratory illness and will be conducted at referral hospitals. The Tarsila Outpatient study will enroll infants with acute respiratory illness managed in outpatient settings and will be conducted at outpatient healthcare facilities. Both studies are aligned with the nationwide introduction of maternal RSVpreF vaccination in December 2025, with enrollment occurring from April, 2026 to September, 2028. In both studies, the same clinical case definition will be applied to cases and controls. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV will be prospectively performed to classify case infants (RT-qPCR positive for RSV) and control infants (RT-qPCR negative for RSV). Maternal RSVpreF vaccination status and potential confounders will be assessed through structured interviews and review of medical records.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Maicon Falavigna, MD PhD
- 전화번호: +55 51 2399 1750
- 이메일: research@inovamedical.com.br
연구 장소
-
-
Paraná
-
Cascavel, Paraná, 브라질, 85818-130
- 모병
- Unidade de Pronto Atendimento Veneza
-
연락하다:
- Maicon Falavigna
- 전화번호: +555123991750
- 이메일: research@inovamedical.com.br
-
Curitiba, Paraná, 브라질, 80060-900
- 모병
- Complexo do Hospital de Clínicas da Universidade Federal do Paraná
-
연락하다:
- Maicon Falavigna
- 전화번호: +555123991750
- 이메일: research@inovamedical.com.br
-
수석 연구원:
- Cristina de Oliveira Rodrigues
-
Curitiba, Paraná, 브라질, 80240-031
- 모병
- Hospital Infantil Pequeno Príncipe
-
연락하다:
- Maicon Falavigna
- 전화번호: +555123991750
- 이메일: research@inovamedical.com.br
-
수석 연구원:
- Heloisa Ihle Garcia Giamberardino
-
Marechal Cândido Rondon, Paraná, 브라질, 85960-000
- 모병
- Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
-
연락하다:
- Maicon Falavigna
- 전화번호: +555123991750
- 이메일: research@inovamedical.com.br
-
Palotina, Paraná, 브라질, 85950-000
- 모병
- Unidade de Saúde Central de Palotina
-
연락하다:
- Maicon Falavigna
- 전화번호: +555123991750
- 이메일: research@inovamedical.com.br
-
Toledo, Paraná, 브라질, 85902-480
- 모병
- Unidade de Pronto Atendimento II de Toledo
-
연락하다:
- Maicon Falavigna
- 전화번호: +555123991750
- 이메일: research@inovamedical.com.br
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 91350-200
- 모병
- Hospital Nossa Senhora da Conceição
-
연락하다:
- Maicon Falavigna, PhD
- 전화번호: +555123991750
- 이메일: research@inovamedical.com.br
-
수석 연구원:
- Fernanda H Varela
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
- 모병
- Hospital de Clínicas de Porto Alegre
-
연락하다:
- Maicon Falavigna
- 전화번호: +555123991750
- 이메일: research@inovamedical.com.br
-
수석 연구원:
- Ricardo Becker Feijó
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Infants with acute respiratory illness (ARI)
설명
Tarsila Inpatient Study
Inclusion Criteria
- Infant born in Brazil.
- Mother resident in Brazil during the related pregnancy.
- Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
- Infant ≤360 days of age at time of RSV specimen collection.
- Infant born at ≥37 weeks of gestational age.
- Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).
Exclusion Criteria:
- Maternal or infant receipt of any other licensed or investigational RSV preventive product.
- Infant receipt of blood transfusion or other blood products containing antibodies since birth.
- Infant previously enrolled in this study.
- Lack of informed consent from the mother or the infant's legal guardian.
- Absent or inconclusive RT-qPCR result for RSV.
- Birth to a mother whose RSVpreF vaccination status could not be confirmed.
Tarsila Outpatient Study
Inclusion Criteria:
- Infant born in Brazil.
- Mother resident in Brazil during the related pregnancy.
- Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
- Infant ≤360 days of age at time of RSV specimen collection.
- Infant born at ≥37 weeks of gestational age.
- Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).
Exclusion Criteria:
- Mother or infant receipt of any other licensed or investigational RSV preventive product.
- Infant receipt of blood transfusion or other blood products containing antibodies since birth.
- Lack of informed consent from the mother or the infant's legal guardian.
- Absent or inconclusive RT-qPCR result for RSV.
- Birth to a mother whose RSVpreF vaccination status could not be confirmed.
- Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: CASE_CONTROL
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Cases
Infants with a positive respiratory syncytial virus result on a nasal swab specimen |
For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery. |
|
Controls
Infants with a negative respiratory syncytial virus result on a nasal swab specimen |
For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth
|
Hospitalization due to RT-qPCR-confirmed RSV-positive lower respiratory tract disease, defined as cough or difficulty breathing, symptom onset within the preceding 10 days, and at least one of the following: tachypnea (respiratory rate ≥60 breaths/min for infants <2 months; ≥50 breaths/min for infants 2-12 months), oxygen saturation (SpO₂) <95%, or chest wall indrawing). |
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)
기간: Occurring ≤180 days after birth.
|
RT-qPCR-confirmed RSV-positive with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring). |
Occurring ≤180 days after birth.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, defined as LRTD plus at least one of the following: respiratory rate ≥70 breaths/min (if <2 months) or ≥60 breaths/min (if ≥2 months); SpO₂ <93%; requirement for high-flow oxygen, non-invasive, or invasive mechanical ventilation; intensive care unit (ICU) admission for >4 hours; or unresponsiveness/loss of consciousness) . |
Hospitalization occurring ≤180 days after birth
|
|
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up to 180 days by Subgroups (Tarsila Outpatient Study)
기간: ARI occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by: gestational age at RSVpreF vaccination, time from RSVpreF vaccination to birth, and time intervals of infant age at illness. |
ARI occurring ≤180 days after birth
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Lower respiratory Tract Disease (LRTD) ICU hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
|
RT-qPCR-confirmed RSV-positive LRTD ICU hospitalization. ICU admission occuring at any point during the index hospitalization. |
Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
|
|
Lower respiratory Tract Disease (LRTD) prolonged hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD long hospital stay (≥11 days) . |
Hospitalization occurring ≤180 days after birth
|
|
Lower respiratory Tract Disease (LRTD) in-hospital death among infants aged up to 180 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
|
RT-qPCR-confirmed RSV-positive LRTD in-hospital death. |
Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
|
|
Hospitalization for lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by time intervals of infant age at illness. |
Hospitalization occurring ≤360 days after birth
|
|
Severe lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Hospitalization for severe lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by time intervals of infant age at illness. |
Hospitalization occurring ≤360 days after birth
|
|
Acute respiratory illness (ARI) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI hospitalization |
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) hospitalization among infants aged up to 360 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive ARI hospitalization. |
Hospitalization occurring ≤360 days after birth
|
|
Lower respiratory Tract Disease (LRTD) Hospitalization due to Human Metapneumovirus (HMPV) among infants aged up to 180 days (Tarsila Inpatient Study)
기간: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed HMPV-positive LRTD hospitalization |
Hospitalization occurring ≤180 days after birth
|
|
Acute Respiratory Illness (ARI) among infants aged up to 180 days by exploratory subgroups (Tarsila Outpatient Study)
기간: ARI occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by:
|
ARI occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up 360 days (Tarsila Outpatient Study)
기간: ARI occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by time intervals of infant age at illness. |
ARI occurring ≤360 days after birth
|
|
Lower respiratory Tract Disease (LRTD) among infants aged up to 180 days (Tarsila Outpatient Study)
기간: LRTD occurring ≤180 days after birth.
|
RT-qPCR-confirmed RSV-positive LRTD. |
LRTD occurring ≤180 days after birth.
|
|
Lower respiratory Tract Disease (LRTD) infants aged up to 360 days (Tarsila Outpatient Study)
기간: LRTD occurring ≤360 days after birth.
|
RT-qPCR-confirmed RSV-positive LRTD. |
LRTD occurring ≤360 days after birth.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Maicon Falavigna, Inova Medical
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- CAAE 95166426.7.1001.0008
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .